Ascendis Pharma’s TransCon CNP Receives FDA Priority Review

The latest update is out from Ascendis Pharma ( (ASND) ).

On June 2, 2025, Ascendis Pharma announced that the FDA has accepted its New Drug Application for TransCon CNP, a treatment for children with achondroplasia, for priority review. The FDA has set a goal date of November 30, 2025, for completing the review and does not plan to hold an advisory committee meeting. This development could significantly impact Ascendis Pharma’s market position by potentially expanding its product offerings in the rare disease treatment sector.

The most recent analyst rating on (ASND) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.

Spark’s Take on ASND Stock

According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.

Ascendis Pharma’s stock reflects a mix of strong revenue growth and innovative product development, offset by significant operational losses and financial instability. The technical analysis shows strong momentum, but valuation remains challenging with negative earnings. The earnings call further underscores the duality of growth potential and financial constraints.

To see Spark’s full report on ASND stock, click here.

More about Ascendis Pharma

Ascendis Pharma is a biopharmaceutical company based in Denmark, primarily focused on developing innovative therapies for rare diseases. The company’s key product offerings include investigational prodrugs designed to provide continuous exposure of active compounds to specific receptors in the body.

Average Trading Volume: 503,073

Technical Sentiment Signal: Strong Buy

Current Market Cap: $9.83B

For an in-depth examination of ASND stock, go to TipRanks’ Stock Analysis page.